HCAHCA Healthcare

$450.93+13% 1Y
Latest close: back above its 200-day averageOct 9, 2026what changed →

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in and cheap vs its sector, but at the top of its own P/E range.

2 good, 1 to watch
What the price assumes~−3% a year

Priced for a decline (~−3% a year). The price demands less than its three-year revenue growth of 8% a year, expectations look modest.

Vs its own P/E rangedearer than 85% of its own historyderived

Expensive vs its own history: P/E 15.5 vs a 12.2 median over 40 quarters (+27% vs median).

Vs sector (EV/EBIT)13.3×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Mar 31, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 68% of the market
FCF yieldbetter than 83% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What HCA's price assumes

HCA Healthcare trades at 15.5× earnings against 20.0× for the median Medical Care Facilities name, cheaper than its own group.

15.5

Trailing P/E · Medical Care Facilities median 20.0 · cheaper than the typical name in its group

Price / sales
1.09

Price / sales · today's price, trailing year to Mar 31, 2026

Free cash flow yield
9.5%

Free cash flow yield · Medical Care Facilities median 7.1%

Growth the price implies
−3.0%

Growth the price implies · The price pays for −3.0% free cash flow growth a year for a decade; the business has delivered +23% a year over the last three.

Details›
EV / EBITtoday's price, trailing year to Mar 31, 2026
13.3
EV / salestoday's price, trailing year to Mar 31, 2026
1.71
Healthcare median P/E509 names
26.2
Medical Care Facilities median P/E33 names
20.0
Free cash flow, trailing twelve months
$7.93B
Market capitalisation
$83.2B
3-year revenue growth
+7.9%
3-year free cash flow growth
+23%
What the market has paid for these earnings: 40 quarters of its own multiple × $29.04 of trailing earnings per share
MethodPer share
Its own P/E history, lower quartile$329.23
Its own P/E history, median$355.73
Its own P/E history, upper quartile$418.11
52-week range$360.60 – $543.23
Today$450.93

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.